ÂÜÀòÂÒÂ×

Dr. Koya is the Director of the Vector Development and Production Facility, and Associate Director of the Center for Immunotherapy at Roswell Park Cancer Institute in Buffalo, NY. He is also an Associate Professor of Oncology and a Member of the Tumor Immunology and Immunotherapy Cancer Center Program. Dr. Koya received his M.D. and completed his clinical residency in Internal Medicine and Fellowship in Clinical Oncology at UFRGS, Porto Alegre, Brazil. He received his Ph.D. in Pathology and Molecular Biology from Hokkaido University in Japan, and performed his post-doctoral fellowship at the Department of Pathology at USC, before becoming an Assistant Professor in the Division of Surgical Oncology within the Department of Surgery at UCLA. Dr. Koya has received many awards, including the Scholar Award from the Ministry of Education and Culture of Japan, the ITO Foundation, The Nickel-V Foundation, and the STOP CANCER Award. His research at Roswell Park focuses on the area of Cancer Gene Therapy and Immunotherapy. Dr. Koya is the author of many high-impact publications in the field of cancer research and currently leads NIH-funded prospective clinical trials based on an immune-modulator-enhanced TCR-engineered T cell transfer for metastatic cancer patients. He serves as a peer-reviewer for various scientific journals in the field of cancer research and immunology and is a grant reviewer in the Scientific Review Study Sections of the National Institute of Health (NIH)/National Cancer Institute (NCI).